EntryPoint Capital’s Soleno Therapeutics SLNO Stock Holding History

EntryPoint Capital’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,766	Closed	-$267K	–	905
2025 Q4	$267K	Buy	+5,766	New	+$316K	0.1%	412
2024 Q2	–	Sell	-135	Closed	-$5.78K	–	1819
2024 Q1	$5.78K	Buy	+135	New	+$6.11K	0.01%	1290

Other funds holding SLNO

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

KCM

Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

EntryPoint Capital's SLNO Position: Q1 2026 in Review

EntryPoint Capital sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 5,766 shares — an estimated $267K sold.

EntryPoint Capital first reported a position in SLNO in Q1 2024 and held it in 2 quarters. The position peaked at $267K in Q4 2025. 226 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

EntryPoint Capital reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
EntryPoint Capital sold 5,766 Soleno Therapeutics shares in Q1 2026, an estimated $267K.
EntryPoint Capital first reported a position in Soleno Therapeutics in Q1 2024 and held it in 2 quarters.
EntryPoint Capital's Soleno Therapeutics position peaked at $267K in Q4 2025.
226 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.